Opinion|Videos|February 29, 2024
Fruquintinib MoA and Toxicity Profile Overview
Key safety considerations for the use of fruquintinib are explored.
Advertisement
Episodes in this series
Advertisement
Related to this article
The FDA set a target action date of February 2027 for the dostarlimab-gxly sBLA in dMMR/MSI-H locally advanced rectal cancer.
ASCO’s ctDNA guidelines support testing for genetic alterations in select scenarios but do not endorse it for residual disease or recurrence monitoring.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Daraxonrasib for Metastatic Pancreatic Ductal Adenocarcinoma
2
Dr Reiss Binder on the FDA Approval of Daraxonrasib for Metastatic PDAC
3
ASCO Issues Warning Regarding Ifosfamide Shortage for Cancer Care
4
Dr Ayanambakkam on the Safety of Darlifarnib Plus Cabozantinib in RCC KD
5